Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-044010
Filing Date
2024-11-07
Accepted
2024-11-07 16:07:19
Documents
60
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 795221
2 ex31-1.htm EX-31.1 21979
3 ex31-2.htm EX-31.2 19722
4 ex32-1.htm EX-32.1 6895
5 ex32-2.htm EX-32.2 6800
  Complete submission text file 0001493152-24-044010.txt   3936825

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE ltrn-20240930.xsd EX-101.SCH 30540
7 XBRL CALCULATION FILE ltrn-20240930_cal.xml EX-101.CAL 44330
8 XBRL DEFINITION FILE ltrn-20240930_def.xml EX-101.DEF 93214
9 XBRL LABEL FILE ltrn-20240930_lab.xml EX-101.LAB 246826
10 XBRL PRESENTATION FILE ltrn-20240930_pre.xml EX-101.PRE 193021
63 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 558483
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

EIN.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 241435601
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)